tirzepatide hfpef trial In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress Another "Positive" Heart Failure Trial
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14












/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788238.jpeg)







.png)








